

Supplemental Table 1.

Risk factors associated with survival, acute and chronic GVHD after HLA-matched unrelated donor transplant

Outcomes	Hazard Ratio (95% confidence interval)	P-value
Overall survival		
<i>Conditioning regimen</i>		
TBI 200 cGy/Cy/ATG	1.00	
TBI 200 cGy/Cy/Fludarabine/ATG	1.29 (0.65 – 2.56)	0.45
Cy/Fludarabine/ATG	1.57 (0.76 – 3.22)	0.22
Cy/ATG	1.10 (0.49 – 2.44)	0.82
<i>Age</i>		
<30 years	1.00	
≥30 years	2.72 (1.64 – 4.52)	<0.001
<i>ATG source</i>		
Equine (h-ATG)	1.00	
Rabbit (r-ATG)	0.55 (0.28 – 1.08)	0.08
<i>Grade II-IV acute GVHD</i>		
<i>Conditioning regimen</i>		
TBI 200 cGy/Cy/ATG	1.00	
TBI 200 cGy/Cy/Fludarabine/ATG	0.49 (0.26 – 0.94)	0.03
Cy/Fludarabine/ATG	0.46 (0.21 – 0.99)	0.05
Cy/ATG	0.76 (0.35 – 1.67)	0.49
<i>ATG source</i>		
Equine (h-ATG)	1.00	
Rabbit (r-ATG)	0.41 (0.22 – 0.76)	<0.001
Chronic GVHD		
<i>Conditioning regimen</i>		
TBI 200 cGy/Cy/ATG	1.00	
TBI 200 cGy/Cy/Fludarabine/ATG	1.07 (0.68 – 1.68)	0.76
Cy/Fludarabine/ATG	0.93 (0.52 – 1.65)	0.79
Cy/ATG	0.86 (0.45 – 1.66)	0.66
<i>Age</i>		
<30 years	1.00	
≥30 years	1.62 (1.08 – 2.41)	0.02
<i>GVHD prophylaxis</i>		
CNI + methotrexate	1.00	
CNI alone / CNI + mycophenolate	1.89 (1.18 – 3.02)	0.008

Abbreviations: ATG = anti-thymocyte globulin; GVHD = graft versus host disease